Direkt zum Inhalt
Merck

MAB8878

Sigma-Aldrich

Anti-Cdk1 Antibody, clone A17.1.1

clone A17.1.1, Chemicon®, from mouse

Synonym(e):

p34cdc2, CDC2

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Biologische Quelle

mouse

Qualitätsniveau

Antikörperform

purified immunoglobulin

Antikörper-Produkttyp

primary antibodies

Klon

A17.1.1, monoclonal

Speziesreaktivität

human, Xenopus, mouse, rat, chicken

Hersteller/Markenname

Chemicon®

Methode(n)

activity assay: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

Isotyp

IgG2a

NCBI-Hinterlegungsnummer

UniProt-Hinterlegungsnummer

Versandbedingung

wet ice

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

mouse ... Cdk1(12534)

Spezifität

Recognizes a 34 kDa protein cdk1, identified as cdk1/p34cdc2 protein kinase (a catalytic subunit of Maturation Promoting Factor). Its epitope maps near the C-terminus of protein and its core is thought to be LGTPNNEV. It shows no cross-reaction with cdk2/p32 and other cyclin dependent kinases (cdks).

Immunogen

Raised against Xenopus p34cdc2.

Anwendung

Research Category
Epigenetik & nukleäre Funktionen
Research Sub Category
Zellzyklus, DNA-Replikation & -Reparatur
Anti-Cdk1 Antibody, clone A17.1.1 is a Mouse Monoclonal Antibody for detection of Cdk1 also known as p34cdc2, CDC2 & has been validated in IF, IP, EA, WB, IHC(P).
Frozen Sections

Immunofluorescence

Immunoprecipitation: (Native/denatured, Protein A; 2μg/mg protein lysate)

Immunohistology (Formalin, 2-4μg/mL for 30 min at RT)

Paraffin Sections (staining requires antigen retrieval).

Western Blotting

Kinase Assay

Optimal working dilutions must be determined by the end user.

p34cdc2, a serine/threonine kinase, is activated by cyclins, presumably by dephosphorylation of tyrosine residues. MAB8878 inhibits the activation of p34cdc2 kinase by cyclins and precipitates an active kinase.

Physikalische Form

Format: Purified
Purified immunoglobulin. 0.2 mg/mL in 10 mM PBS, pH 7.4, containing 0.2% BSA and 0.09% Sodium Azide.

Lagerung und Haltbarkeit

Maintain at 2° to 8°C in undiluted aliquots for up to 12 months from date of receipt.

Hinweis zur Analyse

Control
POSITIVE CONTROL:

HeLa or NIH3T3 cells. Germinal center in a tonsil or reactive lymph node. Cellular localization is predominantly nuclear, with some cytoplasmic staining.

Sonstige Hinweise

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Rechtliche Hinweise

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Empfehlung

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Ian M McDonald et al.
The Journal of biological chemistry, 295(8), 2359-2374 (2020-01-04)
The maternal embryonic leucine zipper kinase (MELK) has been implicated in the regulation of cancer cell proliferation. RNAi-mediated MELK depletion impairs growth and causes G2/M arrest in numerous cancers, but the mechanisms underlying these effects are poorly understood. Furthermore, the
E M Alexandrova et al.
Nature, 523(7560), 352-356 (2015-05-27)
Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance. Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is
Aisling Pierce et al.
Cancer biology & therapy, 14(6), 537-545 (2013-06-14)
PARP inhibitors, both as monotherapy and in combination with cytotoxic drugs, are currently undergoing clinical trials in several different cancer types. In this investigation, we compared the antiproliferative activity of two PARP/putative PARP inhibitors, i.e., olaparib and iniparib, in a
Lucía San Juan et al.
Cell death discovery, 9(1), 21-21 (2023-01-22)
Epithelial transdifferentiation is frequent in tissue hyperplasia and contributes to disease in various degrees. Squamous metaplasia (SQM) precedes epidermoid lung cancer, an aggressive and frequent malignancy, but it is rare in the epithelium of the mammary gland. The mechanisms leading
Jesús Galán-Vidal et al.
Cell death & disease, 15(8), 596-596 (2024-08-17)
Squamous or epidermoid cancer arises in stratified epithelia but also is frequent in the non-epidermoid epithelium of the lung by unclear mechanisms. A poorly studied mitotic checkpoint drives epithelial cells bearing irreparable genetic damage into epidermoid differentiation. We performed an

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.